Hypoglycaemia is the most important adverse effect of treatment with sulphonylureas.' Both accidental and intentional overdosage has been reported in non-diabetic as well as in diabetic subjects.i" but only in those with no history of diabetes mellitus is diagnosis usually difficult and delayed.
CASE REPORT
A 90-year-old woman was brought to the Accident and Emergency Department having been found unconscious at home. She had previously been well, although receiving treatment with ranitidine, frusemide, magnesium sulphate and lactulose from her General Practitioner. On admission, her blood glucose concentration was 0'7mmol/L, plasma urea 7·1 mmol/L(2·5-6·5 mmol/L), creatinine 81 J.Lmol/L(45-120 J.Lmol/ L) aspartate aminotransferase 17 U /L( < 40 U / L), alkaline phosphatase 303 U/L(80-300 U/L) and bilirubin < 20 J.Lmol/L( < 20 J.Lmol/L). She was restored to consciousness by rapid intravenous injection of 50 mL of 50% dextrose, followed by a slow intravenous infusion of glucose at a rate of 8·4 g/h. After 24 h she was permitted food by mouth and the infusion was stopped, but her blood glucose concentration dropped to 2·5 mmol/L, The glucose infusion was restarted and kept going for a further 4 days whilst investigations into the cause of her hypo glycaemia were carried out.
The plasma insulin and C-peptide concentrations, on the specimen collected on admission while the patient was hypoglycaemic, were 27 pmol/L and 839 pmol/L, respectively, and p- in the presence of hypo glycaemia pointed to endogenous hyperinsulinism as the mechanism of hypo glycaemia and of which insulinoma is the most likely cause. Enquiries from the patient's daughter revealed the patient's husband, who was blind, had been prescribed glibenclamide 20 mg per day for his diabetes. The husband said that he regularly gave his wife her medication which was, however, kept separately from his own, and was adamant that no confusion could have occurred. Nevertheless, inadvertent intake of glibenclamide was suspected and measurement of the glibencamide concentration in the blood sample collected on ad-mISSIon, using a sulphonylurea-specific radiomimmunoassay method employing glibenclamide as standard," gave a value of 243 nmol/L (usual therapeutic range, 50-315nmol/L).
DISCUSSION
Sulphonylureas are the most commonly used oral hypoglycaemic agents. Their mode of action is to reduce hepatic glucose production, increase insulin-mediated uptake of glucose in peripheral tissues and stimulate the release of insulin by the pancreatic p cells. Severe, occasionally fatal, hypoglycaemia may complicate sulphonylurea therapy. Elderly patients are more susceptible than younger people to sulphonylurea-induced hypoglycaernia.' Renal impairment and congestive cardiac failure are important contributing factors. The hypoglycaemia is often prolonged due to impaired excretion or metabolism of the offending drug and may last for more than 60 h in spite of continuous infusion of glucose. Treatment with glucagon and/or diazoxide may be required in addition to intravenous glucose in order to prevent a fatal outcome.'
The number of elderly people, many of whom are partially sighted" and in receipt of polyphar-macy is increasing. Accidental intake of drugs, as in the present case, is likely to increase, and unless the possibility of iatrogenic disease is always considered and thoroughly investigated, inappropriate diagnostic procedures and treatments may be carried out. Even more importantly appropriate preventive measures might not be initiated.
